Ajanta Pharma
-
{
- All
- News
- Videos
-
Ajanta Pharma's India, US Momentum Drives Q1 Beat; Jefferies Sees More Upside Ahead
While the brokerage expects competition to weigh on US growth over time, it believes the company's domestic business continues to outperform, with Asia likely to rebound after temporary disruptions linked to the Middle East conflict.
-
Dividend Alert: Ajanta Pharma Announces Interim Dividend — Check Record Date, Payout Date
The company's revenue from operations rose 25% year-on-year (YoY) to Rs 1,626 crore, compared with Rs 1,303 crore in the corresponding quarter last year.
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
'Buy' Ajanta Pharma Shares Maintains Motilal Oswal, Sees 17% Upside — Check Target Price
Valuations remain attractive, with Motilal Oswal reiterating a Buy rating on Ajanta Pharma, implying a 17% upside.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
Corporate Actions This Week: Infosys Buyback; Power Grid, ONGC, And More To Trade Ex-Dividend—Full List
Corporate Actions This Week: The market will focus on major events like the Infosys Ltd. Buy Back of Shares and a special dividend from Premco Global Ltd.
-
Godfrey Phillips, Power Grid, Ajanta Pharma Dividends: Last Day To Buy Shares To Qualify — Details Here
Godfrey Phillips's board announced an interim dividend of Rs 17 per share.
-
Ajanta Pharma Q2 Review — Strong Growth Momentum In The US; Systematix Maintains 'Buy'
The brokerage retains its forecasts on Ajanta and maintains Buy with a target price of Rs 3,293 based on 35x FY27E earnings per share.
-
Ajanta Pharma Announces Rs 28 Dividend — Check Record Date, Other Details
This would amount to a total of Rs 349.82 crore in dividend payout by Ajanta Pharma.
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
-
Ajanta Pharma Poised To Deliver Double Digit Growth, Says Systematix Maintaining 'Buy' Post Strong Q1 Results
Systematix retains its forecasts on Ajanta and maintain Buy with a target price of Rs 3,293 based on 35x FY27E earnings per share.
-
Ajanta Pharma Q1 Net Profit Rises 4% To Rs 255 Crore
Ajanta Pharma net profit rises 4 pc to Rs 255 cr in Jun qtr
-
Sun Pharma, Cipla And More — Nirmal Bang's Top Stock Picks In Pharma Pack; Q1 Results Preview
Nirmal Bang expects Ajanta Pharma, Dr. Reddy's, JB Chemicals, Eris, Sun Pharma, and Lupin to outperform the IPM.
-
Pharma Q4 Results Review — India Traction Healthy; Post gRevlimid Uncertainty Looms, Says ICICI Securities
Pharma Q4 Results Review: Sun Pharma, Cipla, Torrent, Piramal Pharma, Akums and Abbott India among ICICI Securities top picks
-
Ajanta Pharma Q4 Review: Revenue Inline But Margins Contract- Systematix Maintains 'Buy', Cuts Target Price
Systematix retains Buy with a revised target price of Rs 3,293 based on 35x FY27E earnings per share.
-
Ajanta Pharma's India, US Momentum Drives Q1 Beat; Jefferies Sees More Upside Ahead
While the brokerage expects competition to weigh on US growth over time, it believes the company's domestic business continues to outperform, with Asia likely to rebound after temporary disruptions linked to the Middle East conflict.
-
Dividend Alert: Ajanta Pharma Announces Interim Dividend — Check Record Date, Payout Date
The company's revenue from operations rose 25% year-on-year (YoY) to Rs 1,626 crore, compared with Rs 1,303 crore in the corresponding quarter last year.
-
Laurus Labs, Biocon, Rubicon Lead Motilal Oswal’s Top Picks As Q3 Healthcare Outlook Brightens — Check Details
Q3 Healthcare Results Preview: Motilal Oswal sees strong Q3 for Laurus Labs, Biocon; hospitals to drive sector momentum
-
'Buy' Ajanta Pharma Shares Maintains Motilal Oswal, Sees 17% Upside — Check Target Price
Valuations remain attractive, with Motilal Oswal reiterating a Buy rating on Ajanta Pharma, implying a 17% upside.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
Corporate Actions This Week: Infosys Buyback; Power Grid, ONGC, And More To Trade Ex-Dividend—Full List
Corporate Actions This Week: The market will focus on major events like the Infosys Ltd. Buy Back of Shares and a special dividend from Premco Global Ltd.
-
Godfrey Phillips, Power Grid, Ajanta Pharma Dividends: Last Day To Buy Shares To Qualify — Details Here
Godfrey Phillips's board announced an interim dividend of Rs 17 per share.
-
Ajanta Pharma Q2 Review — Strong Growth Momentum In The US; Systematix Maintains 'Buy'
The brokerage retains its forecasts on Ajanta and maintains Buy with a target price of Rs 3,293 based on 35x FY27E earnings per share.
-
Ajanta Pharma Announces Rs 28 Dividend — Check Record Date, Other Details
This would amount to a total of Rs 349.82 crore in dividend payout by Ajanta Pharma.
-
Pharma Sector Sees Modest Growth Amid US Headwinds; Sun Pharma, Cipla Among ICICI Securities' Top Picks
Pharma Q2 Resulte Preview: ICICI Securities remains cautious on the near-term outlook for pharma sector citing US tariffs uncertainty, NLEM price revision in 2026.
-
Ajanta Pharma Poised To Deliver Double Digit Growth, Says Systematix Maintaining 'Buy' Post Strong Q1 Results
Systematix retains its forecasts on Ajanta and maintain Buy with a target price of Rs 3,293 based on 35x FY27E earnings per share.
-
Ajanta Pharma Q1 Net Profit Rises 4% To Rs 255 Crore
Ajanta Pharma net profit rises 4 pc to Rs 255 cr in Jun qtr
-
Sun Pharma, Cipla And More — Nirmal Bang's Top Stock Picks In Pharma Pack; Q1 Results Preview
Nirmal Bang expects Ajanta Pharma, Dr. Reddy's, JB Chemicals, Eris, Sun Pharma, and Lupin to outperform the IPM.
-
Pharma Q4 Results Review — India Traction Healthy; Post gRevlimid Uncertainty Looms, Says ICICI Securities
Pharma Q4 Results Review: Sun Pharma, Cipla, Torrent, Piramal Pharma, Akums and Abbott India among ICICI Securities top picks
-
Ajanta Pharma Q4 Review: Revenue Inline But Margins Contract- Systematix Maintains 'Buy', Cuts Target Price
Systematix retains Buy with a revised target price of Rs 3,293 based on 35x FY27E earnings per share.
